Article Abstract

Drifting EGFR mutation

Authors: Rintaro Noro, Tesshi Yamada


It is generally accepted that somatic mutation in the EGFR gene can serve as a biomarker for predicting the efficacy of treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).


  • There are currently no refbacks.